Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Ovarian Cancer
NCT04606914Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2021
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirvetuximab soravtansine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Progression-Free Survival at 2 years, Objective Response Rate at 2 years and 1 more. Started May 2021; status: recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04606914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606914.